<DOC>
	<DOCNO>NCT02642614</DOCNO>
	<brief_summary>The main objective current trial investigate safety , tolerability , pharmacokinetics effect inflammation oral BI 1026706 administer twice daily 4 week patient COPD .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Effect Inflammation Oral BI 1026706 Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent consistent ICHGCP guideline local legislation prior participation trial . Medication washout medication restriction allow sign informed consent obtain . Males females childbearing potential 40 80 year ( inclusive ) age , day patientÂ´s signature inform consent . All patient must document diagnosis COPD accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) . Postbronchodilator FEV1 &gt; =40 % &lt; =90 % predict normal Visit 1 Postbronchodilator FEV1/FVC &lt; 70 % Visit 1 Patients must current exsmokers smoke history 10 pack year Patients stable respiratory medication least 6 week prior randomization ( Visit 3 ) . Patients must able perform technically acceptable pulmonary function test . Exclusion criterion : Significant pulmonary disease COPD medical condition determine medical history , examination , clinical investigation screen may , opinion investigator , result following : 1 . Put patient risk participation study 2 . Influence result study 3 . Cast doubt patient ability participate study Patients current asthma . For patient allergic rhinitis atopy , source documentation require verify patient asthma . Patients clinically relevant abnormal hematology , blood chemistry , urinalysis screen visit ( Visit 1 ) , abnormality indicate relevant disease define exclusion criterion number 1 . Safety laboratory screen evaluation ( Visit 1 ) repeat maximum two time . Patients history myocardial infarction apoplexy within 6 month screen visit ( Visit 1 ) screen visit ( Visit 1 ) randomization . Patients history and/or active lifethreatening cardiac arrhythmia , assess investigator . Patients mark baseline prolongation QT/QTcB interval ( repeat demonstration QTcB interval &gt; 450 m ) , pulse/heart rate outside 50 90 bpm Visit 1 ( confirm pulse rate measurement 60 second ) , relevant ECG finding . Patients history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) . Patients know active tuberculosis . Patients clinically relevant bronchiectasis , assess investigator . Patients respiratory infection ( common cold , acute sinusitis , similar illness ) COPD exacerbation within 6 week prior screen visit ( Visit 1 ) screen visit randomization . Patients undergone thoracotomy pulmonary resection ( patient history thoracotomy reason evaluate per exclusion criterion No . 1 ) . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last 5 year . Patients treat basal cell carcinoma fully cure squamous cell carcinoma allow participate . Patients history and/or active significant alcohol drug abuse assess investigator . Patients treat nonpermitted concomitant medication . Patients take investigational drug within 4 week prior Visit 1 screening occurs within six halflives intake another investigational drug ( whichever great ) . Patients surgery gastrointestinal tract could interfere kinetics trial medication assess investigator . Patients vein unsuited venipuncture ( instance , vein difficult locate , access puncture , vein tendency rupture puncture ) assess investigator . Patients unable comply dietary regimen . Patients previously randomize study . Patients donate 100 mL blood 4 week prior Visit 1 Visit 1 Visit 3 patient intention donate blood Visit 3 four week end trial visit . Patients pregnant breastfeed Male patient agree minimize risk female partner become pregnant first dose day 3 month trial medication treatment finish . Patient assess unsuitable inclusion investigator ; instance , consider comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>